MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12885-025-14622-x

Медицинская библиотека · BMC cancer · 2025

Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion.

Silva Carlos Sergio Rocha, Teixeira Lisete Ribeiro, Pereira Karina Rocha, Figueiredo Braga Colares Philippe, Alvarenga Vanessa Adelia, Sales Roberta Karla Barbosa, Roque Amanda Cabral, Marchi Evaldo, Mamoni Ronei Luciano, Pagliarelli Acencio Milena Marques

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Malignant pleural effusion (MPE) is a disease associated with poor prognosis, high morbidity, and significant mortality. Murine models of MPE have successfully replicated its formation and metastases, providing valuable insights into potential therapeutic approaches. Nanoparticle-associated drugs (nab) offer the advantage of reduced toxicity while enhancing their effectiveness against tumor cells. This study aims to evaluate the efficacy of intrapleural nab-Paclitaxel, either alone or in combination with anti-vascular endothelial growth factor (VEGF), in a murine model of MPE.

METHODS

Lewis Lung Carcinoma (LLC) cells were injected intrapleurally into 300 mice. After seven days, the mice were assigned to one of five treatment groups: intrapleural administration of Paclitaxel, nab-Paclitaxel, anti-VEGF, nab-Paclitaxel + anti-VEGF, or saline (untreated). Twenty animals per group were monitored weekly for weight, mobility, and survival. Additionally, ten mice from each group were euthanized on days 7, 14, 21 and 28 to assess pleural fluid volume, cytology, lactate dehydrogenase (LDH), interleukin-6 (IL-6), VEGF, transforming necrosis factor (TNF)-α, and histological characteristics.

RESULTS

Pleural carcinomatosis was lethal across all groups; however, mice receiving nab-Paclitaxel + anti-VEGF exhibited the longest survival. Pleural fluid accumulation was most pronounced in the untreated and Paclitaxel groups, whereas the lowest levels were observed in the nab-Paclitaxel + anti-VEGF group. Tumor implantation in the pleura occurred in all groups, but the lowest scores were recorded in mice treated with nab-Paclitaxel + anti-VEGF.

CONCLUSIONS

In this experimental MPE model, intrapleural administration of nab-Paclitaxel in combination with anti-VEGF significantly prolonged survival and reduced both pleural fluid volume and tumor implantation.

Для цитирования: Silva Carlos Sergio Rocha, Teixeira Lisete Ribeiro, Pereira Karina Rocha, Figueiredo Braga Colares Philippe, Alvarenga Vanessa Adelia, Sales Roberta Karla Barbosa, Roque Amanda Cabral, Marchi Evaldo, Mamoni Ronei Luciano, Pagliarelli Acencio Milena Marques. Effect of intrapleural anti-Vascular Endothelial Growth Factor (VEGF) associated with nab paclitaxel in a murine model of malignant pleural effusion.. BMC cancer. 2025. DOI: 10.1186/s12885-025-14622-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.